Inflammation marker ESR is effective in predicting outcome of diffuse large B-cell lymphoma

• Main Authors: Shuang Wu, Ye Zhou, Hai-Ying Hua, Yan Zhang, Wen-Yan Zhu, Zhi-Qing Wang, Jin Li, Hua-Qiang Gao, Xiao-Hong Wu, Ting-Xun Lu, Dong Hua
• Format: Article
• Language: English
• Published: BMC 2018-10-01
• Series: BMC Cancer
• Subjects: Diffuse large B-cell lymphoma; Erythrocyte sedimentation rate; Prognosis; Survival
• Online Access: http://link.springer.com/article/10.1186/s12885-018-4914-4

Abstract Background Systemic inflammation has been implicated in cancer development and progression. This study examined the best cutoff value of erythrocyte sedimentation rate (ESR) in diffuse large B-cell lymphoma (DLBCL) patients. Methods The relationship between ESR and clinical characteristics was analyzed in 182 DLBCL patients from 2006 to 2017. The log-rank test, univariate analysis, and Cox regression analysis were applied to evaluate the relationship between ESR and survival. An ESR of more than 37.5 mm/hour was found to be the optimal threshold value for predicting prognosis. Results ESR was associated with more frequent advanced Ann Arbor stage, poorer performance status, elevated lactate dehydrogenase level, the presence of B symptoms, high-risk International Prognostic Index (IPI 3–5), more extranodal involvement (ENI ≥2), non-germinal-center B-cell (non-GCB) subtypes, and more frequent Myc protein positivity. Shorter overall survival (OS) and progression-free survival (PFS) were found for patients with higher ESRs. Multivariate analysis demonstrated that ESR level is an independent prognostic factor of both OS and PFS. In addition, dynamic changes in ESR are valuable in assessing curative effect and predicting disease recurrence. Conclusion High ESR in DLBCL patients indicated unfavorable prognosis that may require alternative treatment regimens.